Ameriprise
MRTX

Ameriprise’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Ameriprise’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-7,371
Closed -$433K – 4009
2023
Q4 		$433K Sell
7,371
-6
-0.1% -$337 ﹤0.01% 3505
2023
Q3 		$321K Buy
+7,377
New +$263K ﹤0.01% 3568
2023
Q1 		– Sell
-637,130
Closed -$28.9M – 4055
2022
Q4 		$28.9M Sell
637,130
-832,704
-57% -$53.9M 0.01% 1007
2022
Q3 		$103M Buy
1,469,834
+7,848
+0.5% +$581K 0.04% 451
2022
Q2 		$98.2M Sell
1,461,986
-16,467
-1% -$1.05M 0.03% 485
2022
Q1 		$122M Buy
1,478,453
+5,847
+0.4% +$598K 0.04% 459
2021
Q4 		$216M Sell
1,472,606
-112,393
-7% -$17.4M 0.06% 333
2021
Q3 		$280M Buy
1,584,999
+1,167,647
+280% +$188M 0.09% 238
2021
Q2 		$67.4M Buy
417,352
+114,710
+38% +$18.4M 0.02% 664
2021
Q1 		$51.8M Sell
302,642
-2,634
-0.9% -$521K 0.02% 756
2020
Q4 		$67.1M Sell
305,276
-148,161
-33% -$32M 0.02% 611
2020
Q3 		$75.3M Sell
453,437
-45,670
-9% -$6.25M 0.03% 504
2020
Q2 		$57M Buy
499,107
+326,275
+189% +$31.6M 0.02% 571
2020
Q1 		$13.3M Buy
172,832
+82,208
+91% +$7.37M 0.01% 1195
2019
Q4 		$11.7M Sell
90,624
-32,820
-27% -$3.17M ﹤0.01% 1614
2019
Q3 		$9.61M Sell
123,444
-24,123
-16% -$2.26M ﹤0.01% 1717
2019
Q2 		$15.2M Sell
147,567
-5,370
-4% -$418K 0.01% 1380
2019
Q1 		$11.2M Sell
152,937
-52,345
-25% -$3.56M 0.01% 1608
2018
Q4 		$8.7M Buy
205,282
+66,953
+48% +$2.67M ﹤0.01% 1715
2018
Q3 		$6.54M Buy
138,329
+110,296
+393% +$6.14M ﹤0.01% 2171
2018
Q2 		$1.38M Buy
28,033
+16,930
+152% +$639K ﹤0.01% 2891
2018
Q1 		$341K Sell
11,103
-7,575
-41% -$210K ﹤0.01% 3327
2017
Q4 		$341K Buy
+18,678
New +$290K ﹤0.01% 3327

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

Ameriprise's MRTX Position: Q1 2024 in Review

Ameriprise sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 7,371 shares — an estimated $433K sold.

Ameriprise first reported a position in MRTX in Q4 2017 and held it in 23 quarters. The position peaked at $280M in Q3 2021. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • Ameriprise reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Ameriprise sold 7,371 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $433K.
  • Ameriprise first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2017 and held it in 23 quarters.
  • Ameriprise's Mirati Therapeutics, Inc. Common Stock position peaked at $280M in Q3 2021.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Ameriprise's 13F filing for Q1 2024, filed 15 May 2024.